Ambu A S Ord (AMBFF) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, welcome to the AMBU Q1 2026 conference call. I am Valentina, the chorus call operator. I would like to remind you that all participants will be in listen-only mode, and the conference is being recorded. The presentation will be followed by a Q&A session. You can register for questions at any time by pressing star and 1 on your telephone. For operator assistance, please press star and 0. The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Britt Melbud Jensen, CEO. Please go ahead. Thank you very much and good morning, everyone. Welcome to this Q1 2025-26 conference. quarterly call. I'm here this morning with our Chief Financial Officer Henrik Skagbender and we will go through our results and I'll start with a business update. So if we look at page 3 as a start and then moving into slide 4 starting with the headlines for this call. So on the back of a a strong Q1 and even a strong H1 last year. We have delivered a very solid Q1 for this year with strong revenue growth, in particular on our endoscopy business. We said in November that our growth was going to be stronger in the last part of this fiscal year compared to the first part of this year, but we are quite satisfied with the strong start of the year that we have had. In particular, what I want to highlight is that we have had very strong momentum across all our endoscopy business areas. We continue to see a very strong underlying momentum in conversions from reusable endoscopy to single-use, where we are both winning new customers on a very high rate, as well as we are increasing the penetration with existing customers. In particular, we had a strong quarter on respiratory soil, but also the other areas look strong. I'll comment on...